AAPL334.19+7.62 (+2.33%) ▲|ABBV257.58+2.58 (+1.01%) ▲|ABT102.30-1.07 (-1.03%) ▼|ACN181.42+3.51 (+1.97%) ▲|ADBE253.84+5.01 (+2.01%) ▲|AMAT461.61+7.60 (+1.67%) ▲|AMD515.91+12.31 (+2.44%) ▲|AMGN379.07-3.40 (-0.89%) ▼|AMT178.40+5.42 (+3.13%) ▲|AMZN256.82+4.93 (+1.96%) ▲|AVGO364.95+4.12 (+1.14%) ▲|AXP325.17+4.46 (+1.39%) ▲|BA210.76+5.96 (+2.91%) ▲|BAC62.93+0.37 (+0.59%) ▲|BKNG174.68+0.77 (+0.44%) ▲|BLK1,086.52+24.12 (+2.27%) ▲|BMY63.43-0.32 (-0.50%) ▼|BNY162.91+0.32 (+0.20%) ▲|BRK-B507.30+0.30 (+0.06%) ▲|C138.88+0.38 (+0.27%) ▲|CAT821.98+16.98 (+2.11%) ▲|CL87.62-0.28 (-0.32%) ▼|CMCSA25.27+0.10 (+0.38%) ▲|COF208.13+1.02 (+0.49%) ▲|COP136.51-0.53 (-0.39%) ▼|COST904.23+1.85 (+0.21%) ▲|CRM248.79+5.79 (+2.38%) ▲|CSCO111.61+4.17 (+3.88%) ▲|CVS94.34-0.96 (-1.00%) ▼|CVX213.94+1.18 (+0.55%) ▲|DE681.57+3.63 (+0.54%) ▲|DHR200.99+0.46 (+0.23%) ▲|DIS106.61+0.79 (+0.74%) ▲|DUK119.78+0.41 (+0.34%) ▲|EMR151.69+3.32 (+2.24%) ▲|FDX312.90+1.10 (+0.35%) ▲|GD357.12+2.87 (+0.81%) ▲|GE325.80+1.65 (+0.51%) ▲|GEV952.55+28.64 (+3.10%) ▲|GILD144.01-0.80 (-0.55%) ▼|GM86.45+0.33 (+0.38%) ▲|GOOG337.69+7.30 (+2.21%) ▲|GOOGL340.72+8.12 (+2.44%) ▲|GS1,031.89+12.12 (+1.19%) ▲|HD309.43+3.74 (+1.22%) ▲|HON202.80+0.62 (+0.30%) ▲|IBM240.68+6.66 (+2.85%) ▲|INTC103.37+3.05 (+3.04%) ▲|INTU320.00+7.23 (+2.31%) ▲|ISRG367.90+7.44 (+2.06%) ▲|JNJ265.75-0.61 (-0.23%) ▼|JPM356.59+3.03 (+0.86%) ▲|KO88.28+0.45 (+0.51%) ▲|LIN467.02+5.40 (+1.17%) ▲|LLY1,122.11-0.90 (-0.08%) ▼|LMT525.69-4.43 (-0.84%) ▼|LOW198.13+1.54 (+0.78%) ▲|LRCX301.69+3.68 (+1.23%) ▲|MA569.53+4.16 (+0.74%) ▲|MCD253.43+0.38 (+0.15%) ▲|MDLZ62.56+0.09 (+0.14%) ▲|MDT90.62-1.00 (-1.09%) ▼|META650.18+5.80 (+0.90%) ▲|MMM165.16+2.30 (+1.41%) ▲|MO69.10+0.31 (+0.45%) ▲|MRK145.37+0.66 (+0.45%) ▲|MS214.53+1.87 (+0.88%) ▲|MSFT495.34+2.90 (+0.59%) ▲|MU978.14+0.73 (+0.07%) ▲|NEE82.90+0.46 (+0.56%) ▲|NFLX77.06+1.05 (+1.37%) ▲|NKE36.94+0.32 (+0.87%) ▲|NOW132.97+1.80 (+1.37%) ▲|NVDA219.32+0.96 (+0.44%) ▲|ORCL152.94+0.00 (+0.00%) ▲|PEP137.04+0.39 (+0.29%) ▲|PFE27.61-0.05 (-0.16%) ▼|PG145.39+2.42 (+1.69%) ▲|PLTR167.09+1.23 (+0.74%) ▲|PM193.15+3.38 (+1.78%) ▲|QCOM185.31+8.43 (+4.76%) ▲|RTX198.37+0.25 (+0.13%) ▲|SBUX99.00-0.22 (-0.22%) ▼|SCHW106.81-0.53 (-0.49%) ▼|SO88.01+0.26 (+0.30%) ▲|SPG205.14+0.47 (+0.23%) ▲|T26.16+0.61 (+2.39%) ▲|TMO612.04+8.86 (+1.47%) ▲|TMUS183.56+6.40 (+3.61%) ▲|TSLA366.21+2.65 (+0.73%) ▲|TXN271.95+13.13 (+5.07%) ▲|UBER71.92-0.64 (-0.88%) ▼|UNH378.35-9.93 (-2.56%) ▼|UNP284.26-1.53 (-0.53%) ▼|UPS100.12+0.15 (+0.15%) ▲|USB62.83+0.42 (+0.67%) ▲|V371.12+3.91 (+1.06%) ▲|VZ50.63+0.66 (+1.32%) ▲|WFC90.52+1.07 (+1.19%) ▲|WMT106.62+0.89 (+0.84%) ▲|XOM165.55+0.32 (+0.19%) ▲|AAPL334.19+7.62 (+2.33%) ▲|ABBV257.58+2.58 (+1.01%) ▲|ABT102.30-1.07 (-1.03%) ▼|ACN181.42+3.51 (+1.97%) ▲|ADBE253.84+5.01 (+2.01%) ▲|AMAT461.61+7.60 (+1.67%) ▲|AMD515.91+12.31 (+2.44%) ▲|AMGN379.07-3.40 (-0.89%) ▼|AMT178.40+5.42 (+3.13%) ▲|AMZN256.82+4.93 (+1.96%) ▲|AVGO364.95+4.12 (+1.14%) ▲|AXP325.17+4.46 (+1.39%) ▲|BA210.76+5.96 (+2.91%) ▲|BAC62.93+0.37 (+0.59%) ▲|BKNG174.68+0.77 (+0.44%) ▲|BLK1,086.52+24.12 (+2.27%) ▲|BMY63.43-0.32 (-0.50%) ▼|BNY162.91+0.32 (+0.20%) ▲|BRK-B507.30+0.30 (+0.06%) ▲|C138.88+0.38 (+0.27%) ▲|CAT821.98+16.98 (+2.11%) ▲|CL87.62-0.28 (-0.32%) ▼|CMCSA25.27+0.10 (+0.38%) ▲|COF208.13+1.02 (+0.49%) ▲|COP136.51-0.53 (-0.39%) ▼|COST904.23+1.85 (+0.21%) ▲|CRM248.79+5.79 (+2.38%) ▲|CSCO111.61+4.17 (+3.88%) ▲|CVS94.34-0.96 (-1.00%) ▼|CVX213.94+1.18 (+0.55%) ▲|DE681.57+3.63 (+0.54%) ▲|DHR200.99+0.46 (+0.23%) ▲|DIS106.61+0.79 (+0.74%) ▲|DUK119.78+0.41 (+0.34%) ▲|EMR151.69+3.32 (+2.24%) ▲|FDX312.90+1.10 (+0.35%) ▲|GD357.12+2.87 (+0.81%) ▲|GE325.80+1.65 (+0.51%) ▲|GEV952.55+28.64 (+3.10%) ▲|GILD144.01-0.80 (-0.55%) ▼|GM86.45+0.33 (+0.38%) ▲|GOOG337.69+7.30 (+2.21%) ▲|GOOGL340.72+8.12 (+2.44%) ▲|GS1,031.89+12.12 (+1.19%) ▲|HD309.43+3.74 (+1.22%) ▲|HON202.80+0.62 (+0.30%) ▲|IBM240.68+6.66 (+2.85%) ▲|INTC103.37+3.05 (+3.04%) ▲|INTU320.00+7.23 (+2.31%) ▲|ISRG367.90+7.44 (+2.06%) ▲|JNJ265.75-0.61 (-0.23%) ▼|JPM356.59+3.03 (+0.86%) ▲|KO88.28+0.45 (+0.51%) ▲|LIN467.02+5.40 (+1.17%) ▲|LLY1,122.11-0.90 (-0.08%) ▼|LMT525.69-4.43 (-0.84%) ▼|LOW198.13+1.54 (+0.78%) ▲|LRCX301.69+3.68 (+1.23%) ▲|MA569.53+4.16 (+0.74%) ▲|MCD253.43+0.38 (+0.15%) ▲|MDLZ62.56+0.09 (+0.14%) ▲|MDT90.62-1.00 (-1.09%) ▼|META650.18+5.80 (+0.90%) ▲|MMM165.16+2.30 (+1.41%) ▲|MO69.10+0.31 (+0.45%) ▲|MRK145.37+0.66 (+0.45%) ▲|MS214.53+1.87 (+0.88%) ▲|MSFT495.34+2.90 (+0.59%) ▲|MU978.14+0.73 (+0.07%) ▲|NEE82.90+0.46 (+0.56%) ▲|NFLX77.06+1.05 (+1.37%) ▲|NKE36.94+0.32 (+0.87%) ▲|NOW132.97+1.80 (+1.37%) ▲|NVDA219.32+0.96 (+0.44%) ▲|ORCL152.94+0.00 (+0.00%) ▲|PEP137.04+0.39 (+0.29%) ▲|PFE27.61-0.05 (-0.16%) ▼|PG145.39+2.42 (+1.69%) ▲|PLTR167.09+1.23 (+0.74%) ▲|PM193.15+3.38 (+1.78%) ▲|QCOM185.31+8.43 (+4.76%) ▲|RTX198.37+0.25 (+0.13%) ▲|SBUX99.00-0.22 (-0.22%) ▼|SCHW106.81-0.53 (-0.49%) ▼|SO88.01+0.26 (+0.30%) ▲|SPG205.14+0.47 (+0.23%) ▲|T26.16+0.61 (+2.39%) ▲|TMO612.04+8.86 (+1.47%) ▲|TMUS183.56+6.40 (+3.61%) ▲|TSLA366.21+2.65 (+0.73%) ▲|TXN271.95+13.13 (+5.07%) ▲|UBER71.92-0.64 (-0.88%) ▼|UNH378.35-9.93 (-2.56%) ▼|UNP284.26-1.53 (-0.53%) ▼|UPS100.12+0.15 (+0.15%) ▲|USB62.83+0.42 (+0.67%) ▲|V371.12+3.91 (+1.06%) ▲|VZ50.63+0.66 (+1.32%) ▲|WFC90.52+1.07 (+1.19%) ▲|WMT106.62+0.89 (+0.84%) ▲|XOM165.55+0.32 (+0.19%) ▲|
23.1 C
New York
Friday, September 11, 2026

Tag: study

newssourceFORcompanyinformationcontent1releasesmarket

Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025

HAMPTON, N.J., June 14, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data demonstrating that barzolvolimab profoundly improves angioedema at 52 weeks in the Company’s Phase 2 clinical trial in chronic spontaneous urticaria (CSU). Angioedema, characterized by swelling of the deeper dermal layers of the skin and mucous membranes, is a painful, debilitating symptom of CSU that has significant impact on quality of life. It commonly affects the face (lips and eyelids), hands, feet, and genitalia but can also involve the tongue, uvula, soft palate, and pharynx1.

Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

11 of 12 participants (92%) enrolled in the 180mg cohort achieved a complete response

BestOnlineSportsbooks.info Publishes New Report on the Rise of Cryptocurrency in U.S. Sportsbooks

Saint John, Antigua and Barbuda, June 14, 2025 (GLOBE NEWSWIRE) -- BestOnlineSportsbooks.info, a recognized source for sports betting industry insights, today announced the release of a new report exploring the rising integration of cryptocurrency within U.S. online sportsbooks. This comprehensive study outlines the industry-wide shift toward digital currencies and how it is influencing operational practices, user experience, and platform infrastructure.

Gene Solutions and Shenzhen USK Bioscience Forge Strategic Partnership to Establish Next-Generation Sequencing Laboratory in Southern China

SINGAPORE, June 14, 2025 /PRNewswire/ -- Gene Solutions, a leading multinational biotechnology company and Shenzhen USK Bioscience Co., Ltd. (USKBio), a prominent innovator in molecular...

ROCKET ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Rocket Pharmaceuticals, Inc. and Encourages Investors to...

NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (NASDAQ:RCKT) in the United States District Court for the District of New Jersey on behalf of all persons and entities who purchased or otherwise acquired Rocket securities between February 27, 2025 to May 26, 2025, both dates inclusive (the “Class Period”). Investors have until August 11, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

RCKT Investor Notice: Robbins LLP Reminds Shareholders of the Class Action Lawsuit Against Rocket Pharmaceuticals, Inc.

Robbins LLP is Investigating Allegations that Rocket Pharmaceuticals, Inc. (RCKT) Misled Investors Regarding the Viability and Efficacy of RP-A501

Rakuten Medical Selected to Participate in FDA CEO Forum in San Diego

- Engaged with FDA Commissioner on shared commitment to fast, safe, and affordable patient access to innovative therapies SAN DIEGO, June 13, 2025 /PRNewswire/ -- Rakuten...

Arbonne Unveils Innovative Plant-Powered Hair Care Collection Fueled by Scalp Science and Clinical Results

IRVINE, Calif., June 13, 2025 /PRNewswire/ -- Arbonne, a global leader in plant-powered personal care, has officially launched its new Hair Care Collection, a comprehensive...

ROSEN, A LEADING LAW FIRM, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – RCKT

NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) between February 27, 2025 and May 26, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 11, 2025.

DARYL WARD, PH.D., NAMED INTERIM EXECUTIVE DIRECTOR OF THE ASHLEY GIBSON BARNETT MUSEUM OF ART

LAKELAND, Fla., June 13, 2025 /PRNewswire/ -- The Ashley Gibson Barnett Museum of Art (The AGB) at Florida Southern College is pleased to announce the...

CureLab Veterinary’s ElenaVet™ Gene Therapy Delivers 90% Success in Pet-Dog Osteoarthritis Study

Frontiers in Veterinary Science paper reports rapid, significant pain relief with weekly p62-plasmid injections and no significant side-effects BOSTON, June 13, 2025 /PRNewswire/ -- CureLab...

UBC researchers awarded more than $6.5 million from Brain Canada to advance neuroscience research

VANCOUVER, BC, June 13, 2025 /CNW/ - UBC Faculty of Medicine researchers have been awarded more than $6.5 million from Brain Canada's Platform Support...

Trusted Crypto Casinos Are Taking Over Online Gambling in 2025: Exclusive Report By Radcred

Radcred’s exclusive 2025 study reveals the safest, fastest-paying crypto casinos reshaping online gambling. See trends, data, and tips. 
Radcred’s exclusive 2025 study reveals the safest, fastest-paying crypto casinos reshaping online gambling. See trends, data, and tips.

WRJ Design Wins National Attention for Jackson Hole Home as “Ode to Art and Beauty”

LUXE honors design team with cover story featuring project inspired by the majestic Teton landscape, iconic modern architecture and a stunning blue-chip art collection JACKSON...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsStudy

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers